Replies to post #48 on Cubist Pharmaceuticals, Inc. (CBST)

[Telephonics]

News to me

I don't see any news from their research collaboration with Ilypsa to develop a non-antibiotic therapy for Clostridium difficile associated diarrhea (CDAD).
Since they had discontinued the development of HepeX-B, I'm afraid they are still looking for new candidates in preclinical.

If this statement is correct is there any reason status would be reported to SEC???